🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Janet L. Oblinger

Nationwide Children's Hospital

ORCID: 0000-0001-6044-5624

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: “Early phase clinical studies of AR‐42, a histone deacetylase inhibitor, for neurofibromatosis type 2‐associated vestibular schwannomas and meningiomas”.

Early phase clinical studies of AR‐42, a histone deacetylase inhibitor, for neurofibromatosis type 2‐associated vestibular schwannomas and meningiomas

Laryngoscope Investigative Otolaryngology(2021)10.1002/lio2.643

N/A

0.546DataRank · unranked

37 citations

Katharine A. Collier, Sarah S. Burns, Janet L. Oblinger, Edina Shu, Beth A. Miles‐Markley +10 more

Proteasomal pathway inhibition as a potential therapy for NF2-associated meningioma and schwannoma

Neuro-Oncology(2023)10.1093/neuonc/noad037

N/A

0DataRank · unranked

10 citations

Janet L. Oblinger, Roberta L. Beauchamp, Zhenzhen Yin, Serkan Erdin, Priya Koundinya +8 more

Preclinical evaluation of the third-generation, bi-steric mechanistic target of rapamycin complex 1-selective inhibitor RMC-6272 in NF2-deficient models

Neuro-Oncology Advances(2024)10.1093/noajnl/vdae024

N/A

0DataRank · unranked

4 citations

Janet L. Oblinger, Roberta L. Beauchamp, Lili Kosa, Françis Robert, Scott R. Plotkin +3 more